Yes I'm shocked I found this at such a low price. Their drug has proven proof of concept in 3rd line pancreatic cancer and prostate cancer. I like the unique science also no other biotech has metabolism of cancer. Adverse events aren't bad either only 4% of patients had grade 3 or higher adverse events.
$TYME New oral approach aimed at disrupting cancer metabolism SM-88 is an investigational Cancer Metabolism-Based Therapy (CMBTsTM) that has demonstrated responses across 15 different cancers 30 patients enrolled in study with actively progressing metastatic cancer and received only SM-88 therapy 29.8 months median overall survival including 13 months of progression free survival (PFS) without additional therapy 33% of patients (10/30) achieved RECIST complete response (CR) or partial response (PR) 57% of patients (17/30) achieved RECIST stable disease (SD) with a median duration of 11 months https://www.globenewswire.com/news-release/2019/04/08/1798977/0/en/TYME-s-SM-88-First-Human-Study-in-Patients-with-Metastatic-Cancer-Published-in-the-Journal-Investigational-New-Drugs.html
News 
Market Data 
Discover 
